Author:
Tan Yi-Hung Carol,Srivastava Saumya,Won Brian M.,Kanteti Rajani,Arif Qudsia,Husain Aliya N.,Li Hubert,Vigneswaran Wickii T.,Pang Ka-Ming,Kulkarni Prakash,Sattler Martin,Vaidehi Nagarajan,Mambetsariev Isa,Kindler Hedy L.,Wheeler Deric L.,Salgia Ravi
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Molecular Biology
Reference39 articles.
1. Travis, W. D. Pathology of lung cancer. Clin. Chest Med 32, 669–692 (2011).
2. Vavala, T. & Novello, S. SC10.04 second-line therapy and beyond in squamous cell NSCLC. J. Thorac. Oncol. 12, S101–S102 (2017).
3. Janne, P. A. Chemotherapy for malignant pleural mesothelioma. Clin. Lung Cancer 5, 98–106 (2003).
4. Sugarbaker, D. J. et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J. Thorac. Cardiovasc Surg. 117, 54–63 (1999).
5. Kindler, H. L. The emerging role of pemetrexed for the treatment of malignant mesothelioma. Oncology (Williston Park) 18, 49–53 (2004).
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献